JP2019535643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535643A5 JP2019535643A5 JP2019512895A JP2019512895A JP2019535643A5 JP 2019535643 A5 JP2019535643 A5 JP 2019535643A5 JP 2019512895 A JP2019512895 A JP 2019512895A JP 2019512895 A JP2019512895 A JP 2019512895A JP 2019535643 A5 JP2019535643 A5 JP 2019535643A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- composition
- carbamate hydrochloride
- phenylpropyl carbamate
- phenylpropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KAOVAAHCFNYXNJ-SBSPUUFOSA-N [(2r)-2-amino-3-phenylpropyl] carbamate;hydrochloride Chemical compound Cl.NC(=O)OC[C@H](N)CC1=CC=CC=C1 KAOVAAHCFNYXNJ-SBSPUUFOSA-N 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- 208000005793 Restless legs syndrome Diseases 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 208000020925 Bipolar disease Diseases 0.000 claims 5
- -1 phenylpropyl carbamate hydrochloride Chemical compound 0.000 claims 5
- 208000001573 Cataplexy Diseases 0.000 claims 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 4
- 206010041349 Somnolence Diseases 0.000 claims 4
- 201000003631 narcolepsy Diseases 0.000 claims 4
- 239000006260 foam Substances 0.000 claims 3
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- RDUWMEXOUFLPOE-SBSPUUFOSA-N [(2R)-2-amino-3-phenylpropyl]carbamic acid hydrochloride Chemical compound Cl.N[C@@H](CNC(O)=O)CC1=CC=CC=C1 RDUWMEXOUFLPOE-SBSPUUFOSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 238000011109 contamination Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 238000003828 vacuum filtration Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021155292A JP7642506B2 (ja) | 2016-09-06 | 2021-09-24 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
| JP2024161956A JP2024178291A (ja) | 2016-09-06 | 2024-09-19 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383822P | 2016-09-06 | 2016-09-06 | |
| PCT/US2017/050233 WO2018048871A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155292A Division JP7642506B2 (ja) | 2016-09-06 | 2021-09-24 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535643A JP2019535643A (ja) | 2019-12-12 |
| JP2019535643A5 true JP2019535643A5 (https=) | 2020-09-24 |
| JP7219213B2 JP7219213B2 (ja) | 2023-02-07 |
Family
ID=61562003
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512895A Active JP7219213B2 (ja) | 2016-09-06 | 2017-09-06 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
| JP2021155292A Active JP7642506B2 (ja) | 2016-09-06 | 2021-09-24 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
| JP2024161956A Pending JP2024178291A (ja) | 2016-09-06 | 2024-09-19 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155292A Active JP7642506B2 (ja) | 2016-09-06 | 2021-09-24 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
| JP2024161956A Pending JP2024178291A (ja) | 2016-09-06 | 2024-09-19 | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10829443B2 (https=) |
| EP (2) | EP3509582B1 (https=) |
| JP (3) | JP7219213B2 (https=) |
| KR (1) | KR102513800B1 (https=) |
| CN (4) | CN109996540A (https=) |
| CA (1) | CA3036071A1 (https=) |
| DK (1) | DK3509582T3 (https=) |
| ES (1) | ES2970887T3 (https=) |
| FI (1) | FI3509582T3 (https=) |
| MY (1) | MY197630A (https=) |
| PH (1) | PH12019500493A1 (https=) |
| SG (1) | SG11201901998WA (https=) |
| WO (1) | WO2018048871A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| MY197630A (en) | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| WO2020035769A1 (en) | 2018-08-14 | 2020-02-20 | Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| WO2021001457A1 (en) | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| IT202000013855A1 (it) | 2020-06-10 | 2021-12-10 | Flamma Spa | Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| AU2023375326A1 (en) * | 2022-11-07 | 2025-05-22 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| WO2024145545A2 (en) * | 2022-12-30 | 2024-07-04 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| WO2024194718A1 (en) | 2023-03-22 | 2024-09-26 | Unichem Laboratories Limited | A stable pharmaceutical composition and process for preparing thereof |
| CN121816178A (zh) | 2023-05-30 | 2026-04-07 | 艾克萨姆治疗股份有限公司 | 用于治疗患有与阻塞性睡眠呼吸暂停和白天过度嗜睡相关的认知受损的受试者的认知受损的索安非托 |
| KR20260033050A (ko) | 2023-06-29 | 2026-03-10 | 액섬 테라퓨틱스, 인크. | 수유 여성에게 솔리암페톨을 투여하는 방법 |
| WO2025042959A1 (en) | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025165760A1 (en) * | 2024-01-29 | 2025-08-07 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) * | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK1140061T3 (da) | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| RU2202607C2 (ru) | 2000-03-03 | 2003-04-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина |
| US20050080268A1 (en) * | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| EP1890684B1 (en) * | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| ES2344469T3 (es) * | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| CA2905457A1 (en) | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
| JP2016530240A (ja) | 2013-07-12 | 2016-09-29 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ | 禁煙の促進 |
| CA2917702A1 (en) | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| MY197630A (en) * | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| KR101950254B1 (ko) | 2016-09-21 | 2019-02-20 | 유상신 | 차량탑승자의 부재를 감지하는 지능형 카시트 |
| WO2020035769A1 (en) * | 2018-08-14 | 2020-02-20 | Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
-
2017
- 2017-09-06 MY MYPI2019001180A patent/MY197630A/en unknown
- 2017-09-06 CN CN201780065192.6A patent/CN109996540A/zh active Pending
- 2017-09-06 EP EP17849432.4A patent/EP3509582B1/en active Active
- 2017-09-06 US US16/331,069 patent/US10829443B2/en active Active
- 2017-09-06 ES ES17849432T patent/ES2970887T3/es active Active
- 2017-09-06 CN CN202511369602.9A patent/CN121202730A/zh active Pending
- 2017-09-06 SG SG11201901998WA patent/SG11201901998WA/en unknown
- 2017-09-06 DK DK17849432.4T patent/DK3509582T3/da active
- 2017-09-06 WO PCT/US2017/050233 patent/WO2018048871A1/en not_active Ceased
- 2017-09-06 FI FIEP17849432.4T patent/FI3509582T3/fi active
- 2017-09-06 CN CN202511369712.5A patent/CN121202731A/zh active Pending
- 2017-09-06 JP JP2019512895A patent/JP7219213B2/ja active Active
- 2017-09-06 CA CA3036071A patent/CA3036071A1/en not_active Abandoned
- 2017-09-06 CN CN202510706413.XA patent/CN120574152A/zh active Pending
- 2017-09-06 KR KR1020197011279A patent/KR102513800B1/ko active Active
- 2017-09-06 EP EP23218015.8A patent/EP4364794A3/en active Pending
-
2019
- 2019-03-06 PH PH12019500493A patent/PH12019500493A1/en unknown
-
2020
- 2020-11-06 US US17/091,222 patent/US11560354B2/en active Active
-
2021
- 2021-09-24 JP JP2021155292A patent/JP7642506B2/ja active Active
-
2022
- 2022-12-14 US US18/066,000 patent/US12384743B2/en active Active
-
2024
- 2024-09-19 JP JP2024161956A patent/JP2024178291A/ja active Pending
-
2025
- 2025-07-11 US US19/266,767 patent/US20250340509A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535643A5 (https=) | ||
| FI3509582T3 (fi) | (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto | |
| JP2018035160A5 (https=) | ||
| JP2013520424A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2017061547A5 (https=) | ||
| JP2012509321A5 (https=) | ||
| JP2020530837A5 (https=) | ||
| JP2014525470A5 (https=) | ||
| JP2019513140A5 (https=) | ||
| JP2013237682A5 (https=) | ||
| TWI751998B (zh) | 結晶型化合物 | |
| JP2018516883A5 (https=) | ||
| JP2015516425A5 (https=) | ||
| JP2007532560A5 (https=) | ||
| JP2016028085A5 (https=) | ||
| JP2016503010A5 (https=) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| CN110612292A (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
| JP2016513704A5 (https=) | ||
| JP2016539136A5 (https=) | ||
| JP2018520188A (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 | |
| JP6159480B2 (ja) | （−）−フペルジンａの調製 | |
| CN104513171B (zh) | 一种玛咖酰胺的合成方法及其用途 | |
| JP2012508747A5 (https=) |